Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Aspirin and Extended?Release Dipyridamole Capsules, 25 mg/200 mg, a generic version of Aggrenox Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.
According to IQVIA sales data for the 12 month period ending March 2019, the Aggrenox Capsules, 25 mg/200 mg market achieved annual sales of approximately $165.6 million.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
